Benzinga··Vandana SinghPfizer's Braftovi Regimen Achieves Primary Endpoints in Metastatic Colorectal Cancer Trial
Pfizer's Braftovi regimen met primary endpoints in Phase 3 colorectal cancer trial, showing significant improvements in progression-free survival versus standard chemotherapy in BRAF-mutated patients.
PFEFDLPJPcolorectal cancerBraftovi